For Healthcare Professionals

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

clipboard-pencil

About the study

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified presence or absence of variations in the leucine-rich repeated kinase 2 (LRRK2) gene, but also for patients without any verified PD-related genetic variant.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local participant privacy regulations.
  2. Diagnosed with PD within 7 years at the time of initial enrollment (i.e., at time of SAD enrollment for rollover participants), without major motor fluctuations or dyskinesia that may interfere with study treatment and assessments in the opinion of the investigator after consultation with the Sponsor.
  3. Modified Hoehn and Yahr Stage ≤ 3. Key

EXCLUSION CRITERIA

  1. Montreal Cognitive Assessment (MoCA) score less than (<) 23, dementia, or other significant cognitive impairment that, in the opinion of the Investigator, would interfere with study evaluation.
  2. History of any brain surgery for PD or a history of focused ultrasound treatment at any time; or history of neuromodulation procedures.
  3. Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year before Screening.
  4. History of unstable angina, myocardial infarction, chronic heart failure, or clinically significant conduction abnormalities within 1 year before Screening.
  5. Poorly controlled diabetes mellitus, as defined by having dosage adjustment of diabetic medication within 3 months before dosing (Day 1) or glycosylated hemoglobin value greater than or equal to (≥) 8 percent (%) at Screening.
  6. History or positive test result at Screening for human immunodeficiency virus.
  7. History or positive test result at Screening for hepatitis C virus antibody. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 866-633-4636Email iconEmail Study Center

Study’s details


Contition

Parkinson's Disease

Age

35+

Phase

Phase 1

Participants needed

82

Est. Completion Date

Dec 2023

Treatment type

Interventional


Sponsor

Biogen

ClinicalTrials.gov identifier

NCT03976349

Study number

254PD101

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.